Search - tctmd.com

Displaying 1 - 20 of 153

Sort: Relevancy | Date

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

News Daily News

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Michael O'Riordan

November 24, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

May 16, 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

March 12, 2025

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

News Daily News

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

February 14, 2025

January 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

January 24, 2025

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

News Conference News AHA 2024

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

November 16, 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

News Conference News ESC 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

August 31, 2024

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

August 19, 2024

Lower-Dose Edoxaban May Be an Option After Age 80: ENGAGE AF-TIMI 48 Analysis

News Daily News

Lower-Dose Edoxaban May Be an Option After Age 80: ENGAGE AF-TIMI 48 Analysis

July 12, 2024

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

News Daily News

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

Michael O'Riordan

July 09, 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

News Conference News NY Valves 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

June 06, 2024

May 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

May 01, 2024

Diltiazem and DOAC Interaction Increases Bleeding Risk in AF

News Daily News

Diltiazem and DOAC Interaction Increases Bleeding Risk in AF

April 18, 2024

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

News Daily News

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

March 15, 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

News Conference News ISC 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

February 15, 2024

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

News Daily News

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

February 02, 2024

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

SAXOPHONE Bolsters Apixaban for Pediatric Heart Disease

News Daily News

SAXOPHONE Bolsters Apixaban for Pediatric Heart Disease

December 05, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.